Why GlaxoSmithKline plc Is A Great Share For Novice Investors

We tell you why GlaxoSmithKline plc (LON: GSK) could boost your profits.

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

In my series examining some of the FTSE 100‘s top shares from the viewpoint of a novice, today I want to tell you why I think GlaxoSmithKline (LSE: GSK) (NYSE: GSK.US) should be a serious contender for your cash.

I’m not concerned with the company’s current valuation, but instead I’m looking at important long-term investment characteristics. And one of those is where a company comes in the pecking order in its business.

In a field like pharmaceuticals, it takes great clout to make the big differences, and to be secure a company really needs to be among the biggest. As well as big successes, you also need to deal with periods of relative drought, and you need the financial muscle to handle it.

GlaxoSmithKline certainly has that. With an £80bn market capitalization, it’s more than twice as big as its FTSE 100 competitor AstraZeneca. It’s the fifth-largest company in the whole of the FTSE, and the fourth-largest pharmaceuticals company in the world in terms of prescription drug sales.

Technology

One fear facing the traditional “big pharma” business is the possibility of being overtaken by upstarts with fancy new technology, and it’s true that smaller nimbler operations could make, say, massive genetic breakthroughs with much smaller initial cash needs.

But that’s easy: just buy them out. After all, the real cost of development lies not in making the initial discovery, but in getting it past approvals and actually onto the market — it can easily cost half a billion dollars or more from start to finish.

And that takes me on to what I see as another of Glaxo’s key strengths. The firm has been pursuing a strategy of buying up promising-looking small companies for some time, especially in developing biotechnology fields, and it’s almost sure that at least some of those will pay off.

Long term

Sure, there’s going to be some volatility in GlaxoSmithKline shares — its drug development cycle is way longer than the City’s short-term investment horizon, and profits will inevitably vary from year to year. So you need to be prepared for that.

But over the longer term, I think you should be pretty safe. And like most shares I’d think of as good for novices, Glaxo pays a good dividend — over the past five years its yield has varied between 4.4% and 5.5%, and it looks set to continue in that range for at least the next couple of years.

Fashion? Nope

And that kind of brings me back to the beginning, and a last key point in Glaxo’s favour — the business it is in. Technology shares have their moments, and may even do well for years, but technologies tend to become obsolete. And a few business, like retail for example, are often affected by the vagaries of fashion. But there will always be a big market for medicines, and getting cured is never going to go out of fashion.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

> Alan does not own any shares mentioned in this article. The Motley Fool has recommended shares in GlaxoSmithKline.

More on Investing Articles

Investing Articles

Could the JD Sports Fashion share price double in the next five years?

The JD Sports Fashion share price has nearly halved in the past five years. Our writer thinks a proven business…

Read more »

Bus waiting in front of the London Stock Exchange on a sunny day.
Investing Articles

If interest rate cuts are coming, I think these UK growth stocks could soar!

Falling interest could be great news for UK growth stocks, especially those that have been under the cosh recently. Paul…

Read more »

Investing Articles

Are these the best stocks to buy on the FTSE right now?

With the UK stock market on the way to hitting new highs, this Fool is considering which are the best…

Read more »

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Can the Centrica dividend keep on growing?

Christopher Ruane considers some positive factors that might see continued growth in the Centrica dividend -- as well as some…

Read more »

Smiling family of four enjoying breakfast at sunrise while camping
Investing Articles

How I’d turn my £12,000 of savings into passive income of £1,275 a month

This Fool is considering a strategy that he believes can help him achieve a stable passive income stream with a…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

2 top FTSE 250 investment trusts trading at attractive discounts!

This pair of discounted FTSE 250 trusts appear to be on sale right now. Here's why I'd scoop up their…

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

3 things that could push the Lloyds share price to 60p and beyond

The Lloyds share price has broken through 50p. Next step 60p? And then what? Here are some thoughts on what…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

£1,000 in Rolls-Royce shares a year ago would be worth this much now

Rolls-Royce shares have posted one of the best stock market gains of the past 12 months. But what might the…

Read more »